Category: Cardiac Rhythm Management
Boston Scientific launches a clinical trial for its Acuity X4 pacemaker and Reliance 4-Front defibrillator leads, ahead of its bid for U.S. FDA approval of the devices.
keys: boston scientific, bsx, acuity x4, reliance 4-front
Medtronic announces the 1st implantation in a U.S. investigational device exemption trial for its Evera SureScan MRI-safe implantable cardioverter-defibrillator.
Medtronic (NYSE:MDT) said the 1st patient was implanted with its MRI-safe Evera SureScan ICD as part of an investigational device exemption trial in the U.S.
St. Jude Medical meets Wall Street's expectations for its 1st quarter of 2014 with moderate sales growth across its product lines, but shares take a downward turn in morning trading.
Minnesota medtech titan St. Jude Medical (NYSE:STJ) lost a few points on Wall Street today after posting 1st quarter earnings a penny above analysts' consensus estimate.
Boston Scientific gets the FDA's OK for a new generation of defibrillators and heart failure devices, including some of the world's smallest and thinnest ICDs.
Boston Scientific (NYSE:BSX) announced this week that it won FDA approval for its newest suite of cardiac devices, including next-generation defibrillators and heart failure devices.
The FDA expands the indication for Medtronic's cardiac rhythm management devices to include bi-ventricular pacing in certain patients.
Medtronic (NYSE:MDT) said the FDA expanded the indication for some of its cardiac rhythm management devices to include bi-ventricular pacing in certain heart failure patients.
InfoBionic raises $17 million in a Series B financing round supporting its cloud-, smartphone- and web-based remote patient monitoring systems.
Digital health startup InfoBionic secured $17 million in Series B financing in support of its remote patient monitoring platform.
InfoBionic plans to use the funds to commercialize its MoMe monitoring platform, which utilizes cloud, smartphone and web services that connect with sensors worn by patients. The company's current focus is on cardiac arrhythmias.
Medtronic says it won CE Mark approval in the European Union for its Evera MRI SureScan implantable cardiac defibrillator, claiming it as the world's 1st ICD approved for full-body magnetic resonance imaging scans.
Medtronic (NYSE:MDT) said it won CE Mark approval in the European Union for the world's 1st market-cleared implantable cardiac defibrillator that's safe for full-body magnetic resonance imaging scans, its Evera MRI SureScan ICD.
The Evera device is slated for an immediate launch in Europe, according to a press release.